Two medications dominate the conversation around GLP-1 therapy for weight loss in 2026: semaglutide and tirzepatide. Both work on the same general principle — mimicking gut hormones that regulate appetite and blood sugar — but they are not interchangeable, and the differences become more important the longer a patient stays on therapy. This guide breaks down what actually separates the two and how patients can think about choosing between them with their clinician.
How They Work
Semaglutide is a single-receptor agonist. It activates GLP-1 receptors in the gut, brain, and pancreas, which slows gastric emptying, suppresses appetite, and improves insulin sensitivity. It has been in clinical use since 2017 and was the first medication in this class to demonstrate substantial weight loss in patients without diabetes.
Tirzepatide is a dual-receptor agonist. It activates the same GLP-1 receptors as semaglutide, but it also activates GIP receptors, a second gut hormone pathway that appears to amplify the metabolic effects. The dual mechanism is the main reason tirzepatide tends to produce somewhat larger average weight loss in head-to-head clinical trials.
What the Data Actually Shows
In the SURMOUNT-1 trial, patients on the highest dose of tirzepatide lost an average of about 22.5% of their body weight over 72 weeks. In the STEP-1 trial of semaglutide at its highest weight-loss dose, patients lost about 14.9% over a similar period. On paper, that suggests tirzepatide is the stronger option. In practice, the picture is more nuanced.
Trial averages hide a wide distribution. Some patients on semaglutide lose more than 20% of their body weight; some patients on tirzepatide lose closer to 10%. Individual response depends on genetics, baseline metabolic health, adherence, lifestyle changes during therapy, and tolerance of side effects. A patient who cannot tolerate the higher doses of tirzepatide may end up losing less weight on it than they would have on a well-tolerated semaglutide regimen.
Side Effect Profiles
Both medications produce gastrointestinal side effects in a substantial percentage of patients, particularly during dose escalation. Nausea, constipation, diarrhea, and reflux are the most commonly reported. The frequency and severity tend to be similar between the two drugs, but individual patients often report tolerating one significantly better than the other for reasons that are not fully understood. This is one reason some patients switch between the two during a multi-year weight loss journey.
Less common but more serious risks include pancreatitis, gallbladder problems, and a theoretical risk of medullary thyroid cancer that has shown up in animal studies but has not been confirmed in humans. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take either drug. Programs that prescribe semaglutide for weight loss should screen for these conditions during intake.
Cost and Access in 2026
Branded versions of both medications — Wegovy for semaglutide and Zepbound for tirzepatide — remain expensive without insurance coverage, with retail prices well above $1,000 per month. Insurance coverage has expanded but remains inconsistent, particularly for patients without a diabetes diagnosis. This pricing gap is the main reason compounded versions have become a significant share of the market.
Compounded semaglutide and tirzepatide treatment are produced by licensed compounding pharmacies and dispensed under physician supervision. They are not FDA-approved in the same way branded drugs are, and they exist within a specific regulatory framework that patients should understand before starting therapy. Reputable telehealth providers will explain this distinction transparently rather than blurring it.
Choosing Between Them
There is no universal right answer. For most patients starting GLP-1 therapy in 2026, the decision comes down to four factors: how aggressive the weight loss goal is, how much side effect tolerance they have, what their budget looks like over a 12-month horizon, and how their clinician evaluates their individual metabolic profile. Working through these questions with a provider who actively manages dose titration tends to produce better outcomes than picking a medication based on internet research alone.